{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010748","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.062280+00:00","generated_at":"2026-06-17T08:56:26.447128+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SCYNEXIS licenses ibrexafungerp to GSK for $90M upfront plus up to $503M milestones","bullets":["Upfront payment of $90M; eligible for up to $70M regulatory, $115M commercial, $242.5M sales, and $75.5M development milestones.","GSK gets exclusive rights to ibrexafungerp (BREXAFEMME) outside Greater China; SCYNEXIS retains other assets with GSK ROFN.","SCYNEXIS to repay ~$35.4M loan principal plus fees to Hercules/SVB upon receipt of upfront or by June 1, 2023.","Transaction expected to close in Q2 2023, subject to HSR waiting period expiration.","Royalties in mid-single to mid-teen percent on cumulative annual sales."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010748","json":"https://secwatch.observer/filing/0000950170-23-010748.json","markdown":"https://secwatch.observer/filing/0000950170-23-010748.md","text":"https://secwatch.observer/filing/0000950170-23-010748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/0000950170-23-010748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/scyx-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:56:26.447128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18b3c1a0a328a24c9e088b1796944aa8ee9fcaa9","claim":"SCYNEXIS INC entered into License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) valued at $90 million (effective 2023-03-30).","evidence_excerpt":"On March 30, 2023 SCYNEXIS, Inc. entered into a license agreement (the “License Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/0000950170-23-010748-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK)"},{"label":"Value","value":"$90 million"},{"label":"Effective","value":"2023-03-30"}],"fact_type":"material_agreement"},{"claim_id":"ebca643fd8550a70ca0f8df6101ec36f08d0350c","claim":"SCYNEXIS INC amended First Amendment and Consent to Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. valued at approximately $35.4 million.","evidence_excerpt":"In connection with the entering into of the License Agreement, SCYNEXIS entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to SCYNEXIS entering into the License Agreement and SCYNEXIS agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4 million), (ii) the prepayment fee payable under Loan Agreement ($262,500), (iii) the final payment payable under Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023010748/0000950170-23-010748-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A."},{"label":"Value","value":"approximately $35.4 million"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}